首页> 美国卫生研究院文献>other >Considerations for clinical read alignment and mutational profiling using next-generation sequencing
【2h】

Considerations for clinical read alignment and mutational profiling using next-generation sequencing

机译:临床读取校准和突变图谱注意事项使用新一代测序

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Next-generation sequencing technologies are increasingly being applied in clinical settings, however the data are characterized by a range of platform-specific artifacts making downstream analysis problematic and error- prone. One major application of NGS is in the profiling of clinically relevant mutations whereby sequences are aligned to a reference genome and potential mutations assessed and scored. Accurate sequence alignment is pivotal in reliable assessment of potential mutations however selection of appropriate alignment tools is a non-trivial task complicated by the availability of multiple solutions each with its own performance characteristics. Using targeted analysis of BRCA1 as an example, we have simulated and mutated a test dataset based on Illumina sequencing technology. Our findings reveal key differences in the abilities of a range of common commercial and open source alignment tools to facilitate accurate downstream detection of a range of mutations. These observations will be of importance to anyone using NGS to profile mutations in clinical or basic research.
机译:下一代测序技术越来越多地应用于临床,但是数据的特点是一系列特定于平台的工件,从而使下游分析成为问题且容易出错。 NGS的一项主要应用是对临床相关突变进行分析,从而将序列与参考基因组进行比对,并对潜在的突变进行评估和评分。准确的序列比对是对潜在突变进行可靠评估的关键,但是选择合适的比对工具是一项艰巨的任务,因为每个解决方案都有自己的性能特点,因此需要多种解决方案。以BRCA1的靶向分析为例,我们基于Illumina测序技术对测试数据集进行了模拟和变异。我们的发现揭示了一系列常见的商业和开源比对工具在促进精确的下游突变检测方面的能力之间的关键差异。对于在临床或基础研究中使用NGS进行突变分析的任何人来说,这些观察结果都是重要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号